Ping An Biomedical Swings to H1 Profit, Faces Nasdaq Delisting Risk
PASW sits 33% above its 52-week low of $0.11.
Summary
Ping An Biomedical reported a first-half 2026 profit of RMB 4.83 million, but remains at risk of Nasdaq delisting with a November 23, 2026 deadline to regain the $1.00 minimum bid price, likely via a reverse stock split.
Key Events · Earnings and Guidance · PASW
-
H1 2026 Profit Reverses Prior Loss
Net income of RMB 4.83 million (US$0.70 million) for the six months ended March 31, 2026, compared to a loss of RMB 4.23 million a year earlier. Revenue fell 47% to RMB 9.59 million.
-
Nasdaq Delisting Deadline Set
Company received a Nasdaq letter on May 26, 2026 granting an additional 180 days, until November 23, 2026, to regain the $1.00 minimum bid price. Management is evaluating a reverse stock split.
-
Deeply Discounted Private Placements
Closed a 100,000,000-share placement at $0.04 on February 9, 2026 and a 567,000-share placement at $0.15 on March 10, 2026, raising approximately $4.08 million in aggregate.
-
ZDAI Investment Partially Unpaid
Acquired 716,667 shares of Direct Booking Technology (ZDAI) for US$1.72 million; US$990,000 remains payable to Huamaotong International Trading Co., Ltd.
Analysis · PASW · Manufacturing
A first-half 2026 net profit of RMB 4.83 million marks a turnaround from the prior-year loss, yet the filing also confirms ongoing non-compliance with Nasdaq's minimum bid price rule. The company has until November 23, 2026 to regain compliance, likely through a reverse stock split, with the stock trading at $0.1458—far below the $1.00 threshold. Two private placements raised approximately $4.08 million at deeply discounted prices of $0.04 and $0.15 per share, and a $1.72 million investment in Nasdaq-listed ZDAI leaves $990,000 still owed to a related party. The combination of a delisting deadline and heavily dilutive financing at prices well below the $6.00 IPO price underscores the company's precarious capital position.
How filings like this one have moved
In the 30 days to Sep 11, 2026, 35.9% of the 1728 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.06%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PASW was trading at $0.15 on NASDAQ in the Manufacturing sector, with a market capitalization of approximately $3.5M. The 52-week trading range was $0.11 to $1.22. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.